Observational Study

Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this

Lotte C Franken, Eva Roos, Job Saris, Jeanin E van Hooft, Otto M van Delden, Joanne Verheij, Joris I Erdmann, Marc G Besselink, Olivier R Busch, Geertjan van Tienhoven, Thomas M van Gulik

ORCID number: Lotte C Franken 0000-0002-2154-4571; Eva Roos 0000-0002-9912-6409; Job Saris 0000-0002-4430-4597; Jeanin E van Hooft 0000-0002-4424-0079; Otto M van Delden 0000-0003-3342-9367; Joanne Verheij 0000-0003-1283-630X; Joris I Erdmann 0000-0001-8233-1505; Marc G Besselink 0000-0003-2650-9350; Olivier R Busch 0000-0001-9605-6831; Geertjan van Tienhoven 0000-0002-2516-2263; Thomas M van Gulik 1234-1234-1234-1234.

Author contributions: Franken L, Saris J, van Gulik TM designed the research study; Franken LC, Saris J performed the research. van Hooft JE, Roos E, van Delden OM, Verheij J, Besselink MG, Erdmann JJ, Busch OR, van Gulik TM contributed essential reagents or tools; van Tienhoven G contributed essential reagents or tools, interpretation of the data, revised work for important intellectual content; Franken L, Saris J analyzed the data; Roos E, van Gulik TM, van Delden OM, Erdmann JJ, Busch OR, van Gulik TM interpreted the data; Franken L, van Gulik TM, Roos E and van Gulik TM wrote the paper; Van Hooft J, Roos E, van Delden OM, Verheij J, Besselink MG, Erdmann.

Abstract

BACKGROUND
Preoperative biliary drainage in patients with presumed resectable perihilar cholangiocarcinoma (PHC) is hypothesized to promote the occurrence of seeding metastases. Seeding metastases can occur at the surgical scars or at the site of postoperative drains, and in case of percutaneous biliary drainage, at the catheter port-site. To prevent seeding metastases after resection, we routinely treated PHC patients with preoperative radiotherapy (RT) for over 25 years until January 2018.

AIM
To investigate the incidence of seeding metastases following resection of PHC.

METHODS
All patients who underwent resection for pathology proven PHC between January 2000 and March 2019 were included in this retrospective study. Between
Routine preoperative radiotherapy (3 times 3.5 Gray) to prevent the occurrence of seeding metastases within 1 year after resection. In this study, endoscopic biliary drainage was performed in all 41 patients, combined with percutaneous biliary drainage in 4 of these patients. In addition, in 11 patients without biliary drainage, no seeding metastases were found. It was hypothesized that biliary drainage, with perturbation of the tumor, enhances bile contamination with tumor cells, thereby increasing the risk of seeding metastases with bile spill incurred during resection. In an effort to prevent this complication, all patients with resectable PHC at our tertiary center, received three times 3.5 Gray (Gy) external radiation therapy to the primary tumor on three consecutive days before surgery to kill free-floating tumor cells in the bile and destabilize the tumor cells that might be spilled during the operation. This concept of preventive, preoperative radiation therapy and dose regimen was based on a suggestion of a Mayo clinic study and a study in bladder carcinoma in which 3 times 3.5 Gy external radiation therapy had shown to be effective to reduce scar implementation metastases following surgery. Initial results of
twenty-one patients with resected PHC who had undergone preoperative radiation, were promising with none of the patients developing seeding metastases\(^4\).

Seeding metastases resulting from spill of bile during operation may become manifest in the tract of previous abdominal drains or laparotomy scar after resection. In addition, most patients with resectable PHC undergo preoperative biliary drainage which in itself, was thought to promote seeding metastases. Biliary drainage can be performed by two different approaches: Percutaneously or by the endoscopic route. Several studies have suggested that percutaneous biliary drainage carries an additional risk of developing seeding metastases along the catheter tract compared to endoscopic approaches, in which no catheter tract is created. Based on a described incidence of seeding metastases in the catheter tract after percutaneous biliary drainage of 2.6%-6.3%, several Asian authors\(^5\)-\(^10\) suggested that endoscopic biliary drainage should be the preferred approach.

The aim of this study was to update the occurrence of seeding metastases in our institution and evaluate the role of preventive pre-operative low-dose radiotherapy in patients with resectable PHC.

**MATERIALS AND METHODS**

All consecutive patients who underwent resection for pathology proven PHC at the Amsterdam UMC (location AMC) between January 2000 and March 2019 were included in this retrospective study. The need for ethical approval was waived by the Medical Ethics Review Committee of the Amsterdam UMC, location AMC (W19_155).

Whereas patients with intraductal papillary neoplasm of the bile duct (IPNB) were included in this analysis, patients with other final pathology diagnosis were excluded. Patient and tumor characteristics were obtained from a prospectively maintained database including all patients undergoing resection for suspicion of PHC. Data regarding preoperative work-up, biliary drainage, radiotherapy, type of surgery, postoperative course, follow-up and recurrence was collected. Jaundiced patients were treated by endoscopic biliary drainage or percutaneous biliary drainage, or a combination of both, with a preference at our institution for initial endoscopic biliary drainage.

Patients were stratified according to type of biliary drainage, while patients undergoing both percutaneous and endoscopic biliary drainage were analyzed as a separate group. Surgical procedures generally consisted of resection of the extrahepatic bile duct in combination with (extended) hemihepatectomy. After 2009, intra-operative bile sampling for cytology was routinely performed in the majority of the patients. Results of bile cytology were compared between patients undergoing preoperative radiotherapy or not. Standard follow-up after resection was 5 years. Imaging was not standard incorporated in oncological follow-up, but performed when patients showed symptoms of recurrent disease.

Between 2000 and January 2018, patients undergoing resection for PHC were irradiated to 3 times 3.5 Gy to the tumor in the liver hilum, administered on three consecutive days prior to resection. Up to 2004, the hilar area was identified using a conventional simulator, based on the position of the biliary stents. From 2004 onwards, computerized tomography (CT) based planning was used. Throughout, a 3D conformal technique was applied. Patients treated between 2000 and 2012, were also included in the study by Wiggers et al\(^11\). Primary outcome of this study was the occurrence of seeding metastases, defined as metastases occurring in the laparotomy scar or in tracts of previous abdominal drains. Recurrence was defined as radiologically suspected or pathologically proven recurrence and time of recurrence was documented. Peritoneal recurrence, unlike in other studies, was not considered as seeding metastases. Only the initial location of recurrence was registered.

**Statistical analyses**

Descriptive statistics were used to describe the data using statistical product and service solutions version 25 (International Business Machines Corporation, Armonk, NY, United States). The Chi-square test was used to compare the incidence of seeding metastases and the occurrence of tumor cells in bile cytology between groups. Duration of drainage was compared using Mann-Witney \(U\) test.
RESULTS

A total of 171 patients who underwent resection for pathology proven PHC between 2000 and March 2019 were identified (Table 1). The median follow-up of survivors was 36 mo [interquartile range (IQR): 16-81]. Biliary drainage prior to resection was performed in 145 patients (85%). In 81 (56%) patients endoscopic biliary drainage took place, 14 (10%) patients underwent percutaneous biliary drainage and 50 (34%) patients underwent both drainage routes, due to the absence of therapeutic success of one route. Median duration between (first) biliary drainage and surgery was 76 d (IQR: 53-101 d) for endoscopic drainage, 53 d (IQR: 36-80 d) for percutaneous biliary drainage and 76 d (range 61-99 d) for both endoscopic and percutaneous biliary drainage, respectively (P = 0.026). Of these 171 patients, there were 161 patients treated between January 2000-January 2018 and ten patients treated between February 2018 and March 2019.

Radiotherapy

A total of 111 patients (65%) underwent preoperative radiotherapy (3 times 3.5 Gy) to reduce the risk of seeding metastases (Figure 1). As part of another study[12], 13 patients were additionally treated with postoperative radiotherapy (as well as preoperative radiotherapy) between 2000 and 2001 (20 × 2.2 Gy).

Intraoperative bile cytology

After 2009, intraoperative bile cytology was obtained in 76 of 125 patients (61%). Bile cytology showed (suspicion of) tumor cells in 24 of 76 patients (32%) and was negative in 33 of 76 patients (45%). In the remaining patients, bile cytology was inconclusive in 9 (12%) and not assessable in 10 of 76 patients (14%). Malignant cells were found in the conclusive bile samples of 18 of 41 patients (44%) treated with radiotherapy and in 6 of 16 (37%) patients not treated with radiotherapy. No difference in the distribution of positive or negative bile cytology was observed between patients who were treated with preoperative radiotherapy or not (P = 0.660).

Seeding metastases

Two patients with metastases in the laparotomy scar (1.2%) were identified (Figure 1). Both patients had been treated with preoperative radiotherapy and one patient was additionally treated with postoperative radiotherapy. Histopathology showed moderately differentiated adenocarcinoma in both cases and both resections were R1 resections. The seeding metastases occurred 21 and 17 mo after resection, respectively. Overall, the incidence of seeding metastases was 1.4% (1 of 81 patients) after endoscopic biliary drainage, 2% (1 of 50 patients) after combined endoscopic and percutaneous biliary drainage, and 0% after both percutaneous biliary drainage (14 patients) and no biliary drainage (26 patients) (P = 0.852).

DISCUSSION

The hypothesis underlying this study was that low-dose preoperative radiotherapy eradicates free-floating vital tumor cells in bile, thereby reducing the risk of seeding metastases incurred during bile spill at the time of resection. The outcome of this study including 171 patients who had undergone resection for PHC, was that only two patients (1.2%) developed seeding metastases (both at the laparotomy scar). Intraoperative bile cytology showed no significant difference in the presence of tumor cells in bile of patients who underwent preoperative radiotherapy or not.

To our knowledge, literature on application of preoperative radiotherapy in patients with resectable PHC from other centers is lacking. As mentioned above, preoperative radiotherapy was introduced at our institution based on a 20% incidence of seeding metastases reported back in 1999 that has shown a striking decrease to currently 1.2%, suggesting a positive effect of preoperative radiotherapy. However, Wiggers et al[13] published a combined analysis of 234 patients from our institution (Academic Medical Center, Amsterdam and Memorial Sloan Kettering Cancer Center, New York)[13]. This study included 106 patients from the Academic Medical Center (Amsterdam) who were subjected to preoperative radiotherapy and 128 patients from the Memorial Sloan Kettering Cancer Center (New York) who were subjected to preoperative radiotherapy. However, no preoperative radiotherapy is given. The difference in the percentage of seeding metastases between both centers (2 of 106; 1.9% vs 5 of 128; 3.9% P = 0.46) was not significant and the overall incidence was low (3.0%)[13]. Therefore, evidence of a potential benefit of low dose preoperative radiotherapy...
Table 1 Characteristics of patients undergoing resection for perihilar cholangiocarcinoma

| Characteristics                              | Patients with PHC (n = 171) |
|---------------------------------------------|-----------------------------|
| Age, mean ± SD                              | 64 (10)                     |
| Male, n (%)                                 | 104 (61)                    |
| ASA, n (%)                                  |                             |
| 1                                          | 30 (18)                     |
| 2                                          | 112 (65)                    |
| 3                                          | 27 (16)                     |
| Missing                                     | 2 (1)                       |
| Drainage, n (%)                             |                             |
| None                                        | 26 (15)                     |
| Endoscopic biliary drainage                 | 81 (48)                     |
| Percutaneous biliary drainage               | 14 (8)                      |
| Both                                        | 50 (29)                     |
| Bismuth-Corlette type, n (%)                |                             |
| I                                          | 4 (2)                       |
| II                                         | 12 (7)                      |
| IIIa                                        | 85 (50)                     |
| IIIb                                        | 42 (25)                     |
| IV                                          | 24 (14)                     |
| Missing                                     | 4 (2)                       |
| Portal vein embolization, n (%)             | 20 (12)                     |
| Radiotherapy, n (%)                         | 111 (65)                    |
| Resection type, n (%)                       |                             |
| Left hemihepatectomy                        | 61 (36)                     |
| Extended left hemihepatectomy               | 6 (4)                       |
| Right hemihepatectomy                       | 40 (23)                     |
| Extended right hemihepatectomy              | 47 (27)                     |
| Minor liver resection                       | 4 (2)                       |
| External bile duct resection only           | 13 (8)                      |
| + Pancreatoduodenectomy                     | 4 (2)                       |
| + Portal vein reconstruction                | 43 (26)                     |
| 90-d mortality, n (%)                       | 22 (13)                     |
| 90-d morbidity, n (%)                       | 126 (74)                    |
| Severe morbidity (Clavien-Dindo ≥ 3), n (%) | 96 (56)                     |
| Recurrence, n (%)                           | 61 (36)                     |
| Local recurrence                            | 37 (22)                     |
| Liver metastases                            | 10 (6)                      |
| Lung metastases                             | 2 (1)                       |
| Peritoneal metastases                       | 7 (4)                       |
| Other                                       | 5 (3)                       |

SD: Standard deviation; ASA: American society of anesthesiologists.
cannot be delivered, since this would require a randomized study with approximately 1200 patients per arm, which is not feasible for such a rare disease. In view of the incidence of local and distant recurrences and the overall prognosis of PHC, the overall incidence of seeding metastases is clinically less relevant. Hence, in January 2018 we decided to discontinue low dose preoperative radiotherapy. Interestingly, the potential of treatment with stereotactic body radiation therapy for patients with unresectable perihilar cholangiocarcinoma is currently being investigated by multiple groups.

The concept of 3 times 3.5 Gy preoperative radiation therapy to reduce the risk of seeding metastases was based on a study in bladder carcinoma first published in 1969\(^\text{[14]}\). Follow-up studies on the effect of preoperative low-dose radiotherapy in bladder carcinoma however, are lacking while low-dose radiotherapy seems to have been abandoned in these patients. In current literature, indeed, a trend of a lower seeding metastases rate is observed (Table 2)\(^\text{[15-17]}\). For example, incidence reported by investigators from Hokkaido University Hospital decreased from 6.3\% (3 of 48)\(^\text{[14]}\) to 4.5\% (3 of 67)\(^\text{[16]}\) in their publications from 2011 and 2014, respectively. Likewise in Nagoya University Hospital, catheter tract recurrence was reported to be 5.6\% (19 of 339) in a study performed by Kim et al\(^\text{[18]}\) in 2015\(^\text{[19]}\), whilst this decreased to 3.6\% (6 of 168) in a study published in 2017\(^\text{[20]}\). Surgical techniques for resection of PHC have been refined reducing bile spill, which may have contributed to this decrease.

Our reported incidence of 1.2\%, based on one of the largest series on this topic, remains lower than the incidence reported in other studies (up to 6.3\%\(^\text{[15-17]}\)). Several factors may contribute to the development of seeding metastases. As mentioned above, preoperative biliary drainage is thought to increase the risk of seeding metastases by enhancing bile contamination with tumor cells. There are some drainage related factors that potentially influence the development of seeding metastases, one of them being the duration of biliary drainage. A recently published study by Komaya et al\(^\text{[21]}\), including 341 resected PHC patients, did not describe the duration of biliary drainage in their patients, although in another study originating from the same group, duration of percutaneous biliary drainage of 60 d or more was identified as an independent risk factor for the development of catheter tract recurrence in distal and perihilar cholangiocarcinoma\(^\text{[22]}\). In other studies reporting on seeding metastases, duration of biliary drainage was often not reported. In our series, the median duration of biliary drainage of 73 d in case of endoscopic biliary drainage and 77 d after percutaneous biliary drainage. Although this would suggest an increased risk in the majority of our patients, the overall incidence was low (1.2\%). Therefore, we cannot fully exclude the possibility that there was an effect of preoperative radiotherapy based on this series alone.

Related to biliary drainage, the type (endoscopic or percutaneous), placement (proximal or transtumoral) may also play a role. Komaya et al\(^\text{[21]}\) showed that the incidence of seeding metastases was higher after percutaneous biliary drainage (44 of 165, 26.7\%) compared to endoscopic biliary drainage (25 of 150, 16.7\%). Their definition of seeding metastases included right-sided pleural dissemination as well as peritoneal dissemination and catheter tract recurrences, due to the use of the transpleural approach of percutaneous biliary drainage in this cohort, resulting in relatively high seeding metastases rates. Separate analysis of catheter tract recurrence, showed occurrence of catheter tract recurrence in 6 of 164 patients (3.7\%) undergoing percutaneous drainage, while recurrence at the laparotomy scar was not described\(^\text{[21]}\).

In contrary, the previously mentioned study by Wiggers including 234 patients showed no significant difference in the occurrence of seeding metastasis between different drainage approaches: 3.4\% after percutaneous and 2.7\% after endoscopic biliary drainage (\(P = 0.71\))\(^\text{[22]}\).

This study has several limitations, the main limitation being the retrospective design of this single-center study, introducing a significant risk of bias. A direct comparison between patients undergoing preoperative radiation to those who did not is not possible within this study. Before January 2018, patients who did not undergo preoperative radiotherapy (35\%) were not randomly assigned and most likely there was a reason not to treat them with preoperative radiotherapy (for example because they did not undergo biliary drainage or for logistic reasons). For some patients treated after stopping preoperative radiotherapy in January 2018, follow-up might be too short for seeding metastases to develop, as seeding metastases occurred after a median of 17 mo in the study by Wiggers et al\(^\text{[22]}\). In addition, due to the absence of standardized follow-up imaging after resection, not all seeding metastases or recurrences may have been detected. When comparing cytology results of patients with and without radiotherapy, we could not account for viability of the cells. Although cells may stain positively, this does not mean that these cells are still viable.
and therefore, we could have overlooked an effect of radiotherapy. Due to the overall low number of events (seeding metastases), proper statistical analysis was not feasible in this series and confidence limits are huge.
CONCLUSION

The incidence of seeding metastases in patients with resected PHC has decreased and is currently low (1.2% in our institution). As the only center in the world reporting on preventive low-dose radiotherapy, we were unable to deliver evidence of a potential benefit of preoperative radiotherapy and therefore preoperative radiotherapy in patients with resectable PHC has been discontinued in our institution.

ARTICLE HIGHLIGHTS

Research background

Routine preoperative radiotherapy (3 times 3.5 Gray) to prevent the occurrence of seeding metastases was used in our tertiary center for 28 years in patients undergoing resection for perihilar cholangiocarcinoma.

Research motivation

Previous research from our department showed that seeding metastases occurred in up to 20% of the patients undergoing resection of perihilar cholangiocarcinoma.

Research objectives

To investigate the occurrence of seeding metastases among patients with resectable perihilar cholangiocarcinoma.

Research methods

A retrospective study was conducted, including all patients undergoing resection of perihilar cholangiocarcinoma in a larger tertiary center between 2000 and March 2019.

Research results

Seeding metastases occurred in 2 out of 171 patients (1.2%) undergoing resection for perihilar cholangiocarcinoma. These seeding metastases occurred at the laparotomy scar in both patients, after 17 and 21 mo, respectively. Intraoperative bile cytology showed no significant difference in the presence of tumor cells in the bile of patients undergoing preoperative radiotherapy or not.

Research conclusions

The incidence of seeding metastases in patients with resected perihilar cholangiocarcinoma has decreased. Evidence of a potential benefit of preoperative radiotherapy could not be delivered and therefore preoperative radiotherapy in patients with resectable perihilar cholangiocarcinoma has been discontinued in our institution.

Research perspectives

As we are the only center reporting on the use of low-dose radiotherapy to prevent seeding metastases in patients with perihilar cholangiocarcinoma, it is unlikely that other reports on this topic will appear and future research may focus more on the potential of stereotactic body radiation therapy to treat patients with unresectable perihilar cholangiocarcinoma.

REFERENCES

1 ten Hoopen-Neumann H, Gerhards MF, van Gulik TM, Bosma A, Verbeek PC, Gouma DJ. Occurrence of implantation metastases after resection of Klatskin tumors. Dig Surg 1999; 16: 209-213 [PMID: 10436369 DOI: 10.1159/000018729]
2 Buskirk SJ, Gunderson LL, Schild SE, Bender CE, Williams HJ Jr, McIlrath DC, Robinow JS, Tremaine WJ, Martin JK Jr. Analysis of failure after curative irradiation of extrahepatic bile duct carcinoma. Ann Surg 1992; 215: 125-131 [PMID: 1312319 DOI: 10.1097/00000658-199202000-00006]
3 van der Werf-Messing BH. Cancer of the urinary bladder treated by interstitial radium implant. Int J Radiat Oncol Biol Phys 1978; 4: 373-378 [PMID: 689940 DOI: 10.1016/0360-3016(78)90965-2]
4 Gerhards MF, Gonzalez DG, ten Hoopen-Neumann H, van Gulik TM, de Wit LT, Gouma DJ. Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. Eur J Surg Oncol 2000; 26: 480-485 [PMID: 11016470 DOI: 10.1053/ejso.1999.0925]
5 Kawakami H, Kuwataki M, Onodera M, Haba S, Eto K, Ehira N, Ynamoto H, Kudo T, Tanaka E, Hirano S,
Kondo S, Asaka M. Endoscopic nasobiliary drainage is the most suitable preoperative biliary drainage method in the management of patients with hilar cholangiocarcinoma. J Gastroenterol 2011; 46: 242-248 [PMID: 20708606 DOI: 10.1007/s00535-010-0298-1]

6 Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: A propensity score matching analysis of resectable perihilar cholangiocarcinoma. Surgery 2017; 161: 394-404 [PMID: 27712872 DOI: 10.1016/j.surg.2016.08.008]

7 Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg 2010; 97: 1860-1866 [PMID: 20799295 DOI: 10.1002/bjs.7228]

8 Sakata J, Shirai Y, Wakai T, Nomura T, Sakata E, Hatakeyama K. Catheter tract implantation metastases associated with percutaneous biliary drainage for extrabiliary cholangiocarcinoma. World J Gastroenterol 2005; 11: 7024-7027 [PMID: 16417610 DOI: 10.3748/wjg.v11.i44.7024]

9 Kang MJ, Choi YS, Jang JY, Han IW, Kim SW. Catheter tract recurrence after percutaneous biliary drainage for hilar cholangiocarcinoma. World J Surg 2013; 37: 437-442 [PMID: 23188530 DOI: 10.1007/s00268-012-1844-1]

10 Kim KM, Park JW, Lee JK, Lee KH, Lee KT, Shim SG. A Comparison of Preoperative Biliary Drainage Methods for Perihilar Cholangiocarcinoma: Endoscopic vs Percutaneous Transhepatic Biliary Drainage. Gut Liver 2015; 9: 791-799 [PMID: 26087784 DOI: 10.5009/gull14243]

11 Wiggers JK, Groot Koerkamp B, Coelen RJ, Dousset A, van Dieren S, Rauws EA, Schattner MA, van Lienden KP, Brown KT, Beselink MG, van Tienhoven G, Allen PJ, Busch OR, D’Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Verheij J, Jarnagin WR, van Gulik TM. Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. Ann Surg Oncol 2015; 22 Suppl 3: S1156-S1163 [PMID: 26122370 DOI: 10.1245/s10434-015-4676-4]

12 Gerhards MF, van Gulik TM, González González D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27: 173-179 [PMID: 12616432 DOI: 10.1007/s00268-002-6434-1]

13 Koedijk MS, Toesca DAS, von Ebben R, Pollom EL, Chang DT. Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control with Elective Nodal Irradiation. Adv Radiat Oncol 2020; 5: 77-84 [PMID: 32051893 DOI: 10.1016/j.adro.2019.08.003]

14 Koedijk MS, Heijmen BJM, Groot Koerkamp B, Eskens FALM, Sprangers D, Poley JW, van Gent DC, van der Laan LJW, van der Holt B, Willemsen FEJA, Méndez Romero A. Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. BMJ Open 2018; 8: e020731 [PMID: 30327398 DOI: 10.1136/bmjopen-2017-020731]

15 van der Werf-Messing B. Carcinoma of the bladder treated by suprapubic radium implants. The value of additional external irradiation. Eur J Cancer 1969; 5: 277-285 [PMID: 4977652 DOI: 10.1016/0014-2964(69)90078-4]

16 Hirano S, Tanaka E, Tsuchikawa T, Matsumoto J, Kawakami H, Nakamura T, Kurashima Y, Ebihara Y, Shichinohe T. Oncological benefit of preoperative endoscopic biliary drainage in patients with hilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014; 21: 533-540 [PMID: 24464984 DOI: 10.1002/jhbp.76]
